<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05615363</url>
  </required_header>
  <id_info>
    <org_study_id>351-102-00004</org_study_id>
    <nct_id>NCT05615363</nct_id>
  </id_info>
  <brief_title>A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Doseranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the dose response in respect of weight decrease following repeated oral&#xD;
      administration of OPC-131461 at 1, 2, 5, and 10 mg or placebo in patients with CHF with&#xD;
      volume overload despite having received diuretics other than vasopressin antagonists&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2023</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight from baseline to last assessment time point (the day after investigational medicinal product [IMP] administration) by Day 8</measure>
    <time_frame>From baseline (before IMP administration on Day 1) to last assessment time point (the day after IMP administration) by Day 8</time_frame>
    <description>The primary endpoint is the change in body weight from baseline (before IMP administration on Day 1) to last assessment time point (the day after IMP administration) by Day 8.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Cardiac Edema (CHF)</condition>
  <arm_group>
    <arm_group_label>OPC 131461 10mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-131461 5 mg tablet ｘ 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC 131461 5mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-131461 5 mg tablet and placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC 131461 2mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-131461 1 mg tablet ｘ 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC 131461 1mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-131461 1 mg tablet and placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC 131461 10mg group</intervention_name>
    <description>OPC-131461 5 mg tablet x 2，once-daily oral administration for 14 days</description>
    <arm_group_label>OPC 131461 10mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC 131461 5mg group</intervention_name>
    <description>OPC-131461 5 mg tablet and placebo tablet，once-daily oral administration for 14 days</description>
    <arm_group_label>OPC 131461 5mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC 131461 2mg group</intervention_name>
    <description>OPC-131461 1 mg tablet x 2，once-daily oral administration for 14 days</description>
    <arm_group_label>OPC 131461 2mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC 131461 1mg group</intervention_name>
    <description>OPC-131461 1 mg tablet and placebo tablet，once-daily oral administration for 14 days</description>
    <arm_group_label>OPC 131461 1mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet，once-daily oral administration for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with CHF with lower limb edema, pulmonary congestion, or jugular venous&#xD;
             distension due to volume overload.&#xD;
&#xD;
          -  Subjects undergoing any of the following diuretic therapies&#xD;
&#xD;
               -  Loop diuretics at a dosage equivalent to 40 mg/day or more of furosemide&#xD;
                  tablet/fine granule&#xD;
&#xD;
               -  Concomitant administration of a loop diuretic and a thiazide diuretic (including&#xD;
                  similar drugs) at any doses&#xD;
&#xD;
               -  Concomitant administration of a loop diuretic and a mineralocorticoid receptor&#xD;
                  antagonist or potassium-sparing diuretic at any doses&#xD;
&#xD;
          -  Subjects who were currently hospitalized or who are able to be hospitalized&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with acute heart failure&#xD;
&#xD;
          -  Subjects with an assisted circulation device&#xD;
&#xD;
          -  Subjects who cannot sense thirst or who have difficulty in ingesting water&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takehisa Matsumaru</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Harasanshin Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>March 3, 2023</last_update_submitted>
  <last_update_submitted_qc>March 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Edema, Cardiac</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.</ipd_time_frame>
    <ipd_access_criteria>Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

